UPDATE: Piper Jaffray Upgrades Celgene (CELG) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500, Nasdaq set for higher open as investors weigh weaker oil, PPI data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Celgene (CELG) PT Lifted at Nomura Post Q1
April 25, 2014 7:48 AM EDTNomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Celgene (NASDAQ: CELG) and boosted his price target to $252.00 (from $248.00) following Q1 results, saying buyback trumps seasonality.
Somaiya commented, "We are raising EPS estimates and target price to $252 from $248, as Celgene... More
Celgene Corp (CELG) Tops Q1 EPS by 2c
April 24, 2014 7:35 AM EDTCelgene Corp (NASDAQ: CELG) reported Q1 EPS of $1.67, $0.02 better than the analyst estimate of $1.65. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.77 billion.
Net Product Sales Performance
REVLIMID® sales for the first quarter increased 14 percent to $1,144 million and were driven by overall market share, increased duration of... More